Medtronic (NYSE:MDT) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Medtronic (NYSE:MDT) released its quarterly earnings data on Tuesday. The medical technology company reported $1.45 EPS for the quarter, topping the consensus estimate of $1.39 by $0.06, FiscalAI reports. The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.

Medtronic Stock Performance

MDT opened at $90.82 on Tuesday. The firm has a market cap of $116.25 billion, a P/E ratio of 24.35, a PEG ratio of 2.45 and a beta of 0.55. Medtronic has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a 50 day simple moving average of $85.81 and a two-hundred day simple moving average of $85.48. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be given a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Friday, September 25th. Medtronic’s dividend payout ratio is presently 77.21%.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic announced a strategic investment in Pi-Cardia Ltd. to accelerate innovation for complex transcatheter aortic valve replacement (TAVR) procedures. The deal could strengthen Medtronic’s structural-heart portfolio and support longer-term growth, although financial terms were not disclosed. Medtronic Announces Strategic Investment in Pi-Cardia to Accelerate Innovation for Complex TAVR
• Positive Sentiment: Wall Street’s average brokerage recommendation remains equivalent to a Buy, indicating continued confidence in Medtronic’s defensive healthcare profile, cash generation and dividend. However, the article cautions that bullish analyst ratings may be overly optimistic and should not be used alone to make an investment decision. Brokers Suggest Investing in Medtronic
• Neutral Sentiment: Medtronic’s fiscal first-quarter 2027 earnings were scheduled for release before the market opened on Sept. 1. Analysts cited in the previews expected approximately $1.39 in adjusted EPS and $9.54 billion in revenue, making the report the main near-term catalyst for the stock. Medtronic Q1 Earnings on Deck: What to Expect
• Neutral Sentiment: Medtronic is highlighted among stocks to watch as investors await its earnings announcement, but the article provides no company-specific change to its outlook. Medtronic, Dell and 3 Stocks to Watch
• Negative Sentiment: Pre-earnings commentary warned that Medtronic shares could fall following the results, reflecting the risk that earnings, revenue or guidance may not meet elevated expectations. Broader weakness in U.S. equity futures, linked partly to renewed geopolitical tensions and interest-rate concerns, also creates a less supportive market environment. Will Medtronic Stock Rise or Fall After Earnings?

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of Medtronic

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quadrant Capital Group LLC grew its holdings in Medtronic by 0.3% during the 4th quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after buying an additional 101 shares in the last quarter. Rossby Financial LCC grew its stake in Medtronic by 5.1% during the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock valued at $211,000 after acquiring an additional 107 shares in the last quarter. Wealthspire Retirement LLC lifted its position in shares of Medtronic by 5.0% in the fourth quarter. Wealthspire Retirement LLC now owns 2,410 shares of the medical technology company’s stock worth $232,000 after buying an additional 114 shares in the last quarter. Mitchell Mcleod Pugh & Williams Inc. raised its holdings in shares of Medtronic by 2.0% during the 4th quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 6,043 shares of the medical technology company’s stock worth $622,000 after acquiring an additional 117 shares in the last quarter. Finally, Florida Financial Advisors LLC boosted its position in shares of Medtronic by 4.8% during the 2nd quarter. Florida Financial Advisors LLC now owns 2,683 shares of the medical technology company’s stock valued at $234,000 after acquiring an additional 122 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MDT shares. Truist Financial lowered their price objective on shares of Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. The Goldman Sachs Group dropped their price target on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Royal Bank Of Canada reissued an “outperform” rating and issued a $118.00 target price on shares of Medtronic in a research report on Thursday, June 4th. Leerink Partners lowered their price objective on shares of Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research note on Thursday, June 4th. Finally, BTIG Research restated a “buy” rating and set a $91.00 target price on shares of Medtronic in a research report on Tuesday, August 18th. Eighteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.79.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).